exerted synergistic effects on imatinib resistance by inhibiting HDAC2 and the PI3K/Akt signal transduction pathway in chronic myelogenous leukemia (CML) cells with imatinib resistance [107]. Here, AKT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.